Description

DURECT Corporation, a biopharmaceutical company, researches and develops therapies based on its epigenomic regulator program and proprietary drug delivery platforms. The company offers ALZET product line that includes osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials for pharmaceutical and medical devices under the LACTEL brand. It also develops DUR-928, an endogenous bioavailable small molecule that is in Phase Ib clinical trial for the treatment of chronic metabolic disease, as well as to treat acute organ injury, including acute kidney injury and other conditions. In addition, the company develops POSIMIR, a formulation of bupivacaine that is in Phase III clinical trial for the treatment of post-surgical pain; REMOXY, an oral oxycodone gelatin capsule for chronic pain; ORADUR-ADHD, a drug candidate, which is in Phase III clinical trial for the treatment of attention deficit hyperactivity disorder; and ELADUR, a transdermal bupivacaine patch for the treatment of pain.. Further, it develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar I disorder in adults and teenagers; ORADUR-based opioid for chronic pain; and various research programs for medical diseases and conditions, such as central nervous system diseases and disorders, cardiovascular diseases, ophthalmic conditions, and metabolic disorders. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, Japan, Europe, and internationally. The company has collaboration agreements with Santen Pharmaceutical Co., Ltd.; Impax Laboratories, Inc.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.